Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Insomnia Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Insomnia Overview | 10 | 1 |
| Pipeline Products for Insomnia Comparative Analysis | 11 | 1 |
| Insomnia Therapeutics under Development by Companies | 12 | 2 |
| Insomnia Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Insomnia Pipeline Products Glance | 15 | 3 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Insomnia Products under Development by Companies | 18 | 1 |
| Insomnia Products under Investigation by Universities/Institutes | 19 | 1 |
| Insomnia Companies Involved in Therapeutics Development | 20 | 16 |
| Actelion Ltd | 20 | 1 |
| Alexza Pharmaceuticals, Inc. | 21 | 1 |
| Eisai Co., Ltd. | 22 | 1 |
| Evotec AG | 23 | 1 |
| Grupo Ferrer Internacional, S.A. | 24 | 1 |
| Heptares Therapeutics Limited | 25 | 1 |
| Intec Pharma Ltd | 26 | 1 |
| Intra-Cellular Therapies, Inc. | 27 | 1 |
| Johnson &Johnson | 28 | 1 |
| Leading BioSciences, Inc. | 29 | 1 |
| Merck &Co., Inc. | 30 | 1 |
| Neurim Pharmaceuticals Ltd | 31 | 1 |
| Novartis AG | 32 | 1 |
| Reviva Pharmaceuticals Inc. | 33 | 1 |
| Shionogi &Co., Ltd. | 34 | 1 |
| Takeda Pharmaceutical Company Limited | 35 | 1 |
| Insomnia Therapeutics Assessment | 36 | 9 |
| Assessment by Monotherapy Products | 36 | 1 |
| Assessment by Combination Products | 37 | 1 |
| Assessment by Target | 38 | 2 |
| Assessment by Mechanism of Action | 40 | 2 |
| Assessment by Route of Administration | 42 | 2 |
| Assessment by Molecule Type | 44 | 1 |
| Drug Profiles | 45 | 40 |
| (diphenhydramine + lorazepam + zolpidem tartrate) Drug Profile | 45 | 1 |
| ACT-541468 Drug Profile | 46 | 1 |
| CB-2810 Drug Profile | 47 | 1 |
| DORA-12 Drug Profile | 48 | 1 |
| Drug for Insomnia Drug Profile | 49 | 1 |
| Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia Drug Profile | 50 | 1 |
| EVT-201 Drug Profile | 51 | 1 |
| HTL-6641 Drug Profile | 52 | 1 |
| ITI-007 Drug Profile | 53 | 8 |
| JNJ-42847922 Drug Profile | 61 | 3 |
| JNJ-48816274 Drug Profile | 64 | 1 |
| LASSBio-785 Drug Profile | 65 | 1 |
| LASSBio-786 Drug Profile | 66 | 1 |
| lemborexant Drug Profile | 67 | 2 |
| lorediplon Drug Profile | 69 | 1 |
| MK-8133 Drug Profile | 70 | 1 |
| NEO-1940 Drug Profile | 71 | 1 |
| piromelatine Drug Profile | 72 | 2 |
| ramelteon Drug Profile | 74 | 1 |
| S-117957 Drug Profile | 75 | 1 |
| Small Molecule for Insomnia, Obesity and Treatment Resistant Depression Drug Profile | 76 | 1 |
| Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia Drug Profile | 77 | 1 |
| Small Molecule to Inhibit OX2R for Insomnia Drug Profile | 78 | 1 |
| Small Molecules to Activate CYP1A2 for Insomnia and Anxiety Drug Profile | 79 | 1 |
| UCM-765 Drug Profile | 80 | 1 |
| zaleplon Drug Profile | 81 | 1 |
| zaleplon Drug Profile | 82 | 2 |
| zolpidem tartrate Drug Profile | 84 | 1 |
| Insomnia Dormant Projects | 85 | 3 |
| Insomnia Discontinued Products | 88 | 1 |
| Insomnia Product Development Milestones | 89 | 11 |
| Featured News &Press Releases | 89 | 1 |
| Sep 08, 2016: Ergomed Completes Recruitment of Phase IIa Clinical Trial of Lorediplon in Insomnia in Collaboration with co-development Partner Ferrer | 89 | 1 |
| Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia | 89 | 1 |
| Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202 | 90 | 1 |
| Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients | 91 | 1 |
| Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder | 91 | 1 |
| Dec 16, 2015: Intec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Zaleplon in Europe | 92 | 1 |
| Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202 | 92 | 1 |
| Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist | 92 | 1 |
| Jul 14, 2015: Ferrer initiates phase IIa clinical study of Lorediplon in patients with insomnia | 93 | 1 |
| Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist | 94 | 1 |
| Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia | 95 | 1 |
| Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance | 96 | 1 |
| Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial | 97 | 1 |
| Jul 26, 2013: Takeda Pharma Receives FDA Approval For Rozerem | 98 | 1 |
| Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia | 98 | 2 |
| Appendix | 100 | 2 |
| Methodology | 100 | 1 |
| Coverage | 100 | 1 |
| Secondary Research | 100 | 1 |
| Primary Research | 100 | 1 |
| Expert Panel Validation | 100 | 1 |
| Contact Us | 100 | 1 |
| Disclaimer | 101 | 1 |